Drug Profile
Research programme: ophthalmic antioxidants - Alimera Sciences
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Alimera Sciences
- Class Small molecules
- Mechanism of Action NADPH oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetic retinopathy; Dry age-related macular degeneration
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Diabetic-retinopathy in USA
- 04 Nov 2017 No recent reports of development identified for research development in Dry age-related macular degeneration in USA
- 18 May 2012 Preclinical development is ongoing in the USA